MIRA INFORM REPORT

 

 

Report No. :

345833

Report Date :

20.10.2015

 

IDENTIFICATION DETAILS

 

Name :

MEDICRAFT PHARMACEUTICALS (PVT.) LIMITED

 

 

Registered Office :

Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar

 

 

Country :

Pakistan

 

 

Year of Establishment :

1991

 

 

Com. Reg. No.:

0024422

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products.

 

 

No. of Employees :

102

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Pakistan

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

Company Name

                       

Business Name

MEDICRAFT PHARMACEUTICALS (PVT.) LIMITED

 

 

Full Address       

 

Registered Address & Factory

Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar, Pakistan

                       

Tel #

92 (91) 5816000, 5891238

Fax #

92 (91) 5891238

 

 

Short Description Of Business

 

a.

Nature of Business       

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

1991

c.

Registration #

0024422

 

 

Branches

 

In Peshawar at present

 

 

Auditors

           

Ghafoor & Co.

(Chartered Accountants)

 

 

Legal Status

 

Subject Company was established as a Private Limited Company in 1991

 

 

Capital

 

Authorized Capital    

Rs. 30,000,000/- divided into 300,000 shares of Rs. 100/- each

Issued & Paid up Capital

Rs 13,510,000/- divided into 135,100 shares of Rs. 100/- each

 

 

Details of Directors

 

Names

 

Nationality

Address

Occupation

Designation

Mr. Ishtiaq Ahmed

 

 

 

 

Mr. Aftab Ahmed

 

 

 

 

Mr. Ashfaq Ahmed

 

 

 

 

Mr. Imtiaz Ahmed

Pakistani

 

 

 

 

Pakistani

 

 

 

 

Pakistani

 

 

 

 

Pakistani

Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar

 

Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar

 

Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar

 

Plot # 126-B, Industrial Estate, Jamrud Road, Peshawar

Business

 

 

 

 

Business

 

 

 

 

Business

 

 

 

 

Business

Chief Executive

 

 

 

 

Director

 

 

 

 

Director

 

 

 

 

Director

 

 

Shareholders                

 

Names

 

No. of Shares

Mr. Aftab Ahmed

 

Mr. Ishtiaq Ahmed

 

Mr. Ashfaq Ahmed

 

Mr. Imtiaz Ahmed

 

Mrs. Ashrafat Begum

 

Mrs. Abida Aftab

 

Mrs. Robina Ishtiaq

15,733

 

46,507

 

41,355

 

27,105

 

1,080

 

920

 

750

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

None                                             

           

B.         Associated Companies

- Do -

 

 

Products

 

Manufacture & Marketing of Pharmaceutical Products by its brand name including ALLERGON, AMCHLO, AMNORIL, ANHIBIT, ASTHACURE, BACTIMED, BACTIRID, BIOMED, BONEMED, CARDIOWEL, CEFOMED, CEFPOMED, CHLOROMED, CIPROKING, CIPROMED, CLIK, CT-COLIN, CTZINE, DEPCURE, DICLOKING, DYRID-P, ENZOVIT, EPIGRAL, FCOZOLE, FOLVIT, GYNEMED, IROMED, KEFZOMED, KUFRID, LEVOMED, LINKOWIN, LIPOMED, LOROKING, MALACURE, MALSIM, MEDFEN, MEDGEL, MEDGLOBIN, MEDIKUF, MEDIMOX, MEDIPLEX - L, MEDIRON, METFORMED, METRONIDAZOLE, MOTIL, NEUROZIN, NOXACIN, OFLOMED, OFLOWIN, OMED, OZAPINE, PAINRID, PARADEXAMOL, PARAMED, PAYARAM, PEPCIMED, PERIACTONE, PHENOMED, PMALAMED, POSTAGLIN, RANMIC, RELAXAMED, RESPIDONE, RIDBAC, SIGMA, TBRID, TIZMED, TREMOMED, ULCERID, ULTOMED, UNIVIT, UNIVIT-M, VEENA FORTE, VELOMED, VENTOMED

 

 

Number of Employees

 

102

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2014

90,000,000/- (Estimated)

 

 

Trade Suppliers (Foreign)

 

Subject import globally from Companies belongs to India, China & European Countries                  

 

 

Customers

 

Major customers are Private & Government Hospitals, Distribution Companies etc

 

 

Bankers

           

(1) Habib Bank Limited, Pakistan.

(2) Dubai Islamic Bank Pak Limited, Pakistan.

(3) Bank Alfalah Limited, Pakistan.

(4) MCB Bank Limited, Pakistan.

(5) United Bank Limited, Pakistan.

 

 

Memberships

 

·         Khyber Pakhtoonkwa Chamber of Commerce & Industry.(KPCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

          Rs. 104.45

UK Pound

1

          Rs. 160.50

Euro

1

          Rs. 118.25

           

 

Comments

 

Subject Company was established in 1991 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.64.82

UK Pound

1

Rs.100.12

Euro

1

Rs.73.75

 

INFORMATION DETAILS

 

Analysis Done by :

KAS

 

 

Report Prepared by :

NIT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.